目的 对连花清瘟联合西医常规治疗新型冠状病毒肺炎（coronavirus disease 2019，COVID-19）的系统评价/Meta分析进行再评价。方法 系统检索中国知网、万方、中国生物医学文献数据库（CBM）、维普（VIP）、PubMed、Embase、Cochrane Library、Web of Science数据库中有关连花清瘟联合西医常规治疗COVID-19的系统评价/Meta分析，检索时间截至2021年10月1日。由2名研究者根据纳入与排除标准筛选文献，确定最终纳入文献。使用AMSTAR-2量表、GRADE系统、PRISMA声明对文献进行方法学质量评价与证据质量分级。结果 共纳入10篇系统评价/Meta分析，包括中文6篇、英文4篇。质量评价和证据质量分级结果显示文献质量和证据等级较低。结论 现有证据显示连花清瘟联合西医常规治疗COVID-19具有较好的疗效，但鉴于系统评价/Meta分析的方法学质量及证据质量等级偏低，尚需开展更多高质量研究以获取高质量的研究结果去验证。

Objective Overview the systematic review/Meta analysis of Lianhua Qingwen (连花清瘟) combined with conventional western medicine in the treatment of coronavirus disease 2019 (COVID-19). Methods Systematic reviews/Meta-analysis of Lianhua Qingwen combined with western conventional in the treatment of COVID-19 from CNKI, Wanfang, CBM, VIP, PubMed, Embase, Cochrane Library, and Web of Science were search, retrieved as of October 1, 2021. Two investigators screened the literature according to the inclusion and exclusion criteria, and determined the final inclusion of the literature. AMSTAR-2 scale, GRADE system, and PRISMA statements were used to evaluate the methodological quality and GRADE the evidence quality. Results A total of eight systematic reviews/Meta analyses were included, including six in Chinese and four in English. The quality evaluation and evidence quality classification results show that the quality of the literature and the level of evidence were low. Conclusion The existing evidence shows that Lianhua Qingwen combined with conventional western has a good effect in the treatment of COVID-19. However, due to the low methodological quality and evidence quality level of the systematic review/Meta analysis and the low level of evidence quality, more high-quality researchs are needed to obtain high-quality research results for verification.

R285.64

中国中医科学院优秀青年科技人才培养专项（ZZ13YQ127）